 BeyondSpring the Company or BeyondSpring BYSI, a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced positive topline results at the pre-specified interim analysis of its PROTECTIVE-2 Study 106 Phase 3 trial, evaluating Plinabulin in combination with Neulasta versus Neulasta alone. Neulasta is a long-lasting G-CSF that is the current standard of care for treating chemotherapy-induced neutropenia CIN. 